This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and
safety study. Eligible patients are enrolled in a single group. The investigators propose to
determine the efficacy and safety of low-dose metronomic chemotherapy with
Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with
Anthracyclines and/or Taxanes.